Advances in stent design and the development of bioresorbable polymers have allowed the
development of novel stent technologies such as the Orsiro bioresorbable-polymer sirolimus …

Aim The aim of this study was to establish safety and efficacy of a new sirolimus-eluting stent
with bioresorbable polymer, Ultimaster (BP-SES). Sirolimus-eluting stent with bioresorbable …

Background: Coronary drug-eluting stent development has introduced new metal alloys,
changes in stent architecture, and bioresorbable polymers. Whether these advancements …

Objectives The aim of this study was to compare late-term clinical outcomes among patients
treated with ultrathin-strut (60-μm) bioresorbable-polymer sirolimus-eluting stents (BP SES) …

Background: The ultrathin-strut bioresorbable-polymer sirolimus-eluting stent (BP-SES)
demonstrated comparable performance to durable-polymer everolimus-eluting stent (DP …

Drug-eluting stents (DES) have revolutionised the treatment of coronary artery disease
(CAD) in patients undergoing percutaneous coronary intervention. In recent years, there has …

Aims The aim of this study was to establish the long-term safety and efficacy of a sirolimus-
eluting stent with bioresorbable polymer (BP-SES; Ultimaster) by comparison with an …

Background Ultrathin strut coronary drug‐eluting stents (DES) have demonstrated improved
safety and efficacy in large contemporary trials. The evaluation of an ultrathin strut DES in a …

Aims: We performed a randomised controlled open-label non-inferiority trial to compare
angiographic outcomes between the ultra-thin strut, biodegradable hybrid polymer Orsiro …

Background Randomized trials have demonstrated the superiority of ultrathin strut drug-
eluting stents compared with alternative stent designs. Whether these differences persist …